

CLAIMS

1. Tetrapeptide lysyl-glutamyl-aspartyl-tryptophane amid of the general formula Lys-Glu-Asp-Trp-NH₂ [SEQ ID NO:1].
2. Tetrapeptide lysyl-glutamyl-aspartyl-tryptophane amid of the general formula Lys-Glu-Asp-Trp-NH₂ of sequence 1 [SEQ ID NO:1] revealing biological activity of glucose level regulating.
3. Pharmaceutical substance composition of peptide nature, capable of regulating glucose level; containing an active peptide agent and a pharmaceutically admissible carrier, which is distinguished by the fact that it contains as its active base an effective quantity of tetrapeptide Lys-Glu-Asp-Trp-NH₂.
4. The substance described in claim 3, wherein said substance is presented in a form suitable for oral administration.
5. The substance described in claim 3, wherein said substance is presented in a form suitable for parenteral administration.
6. The method of prophylaxis and/or treatment of diabetes mellitus, which consists in administering to the patient of the pharmacological substance, containing as an active peptide agent an effective amount of Lys-Glu-Asp-Trp-NH₂ tetrapeptide in doses of 0,1 – 30 µg/kg of the body weight at least once a day for a period necessary for attaining a therapeutic effect.
7. The method of claim 6 wherein the pharmacological substance is intended for parenteral administration.
8. The method of claim 6 wherein the pharmacological substance is intended for oral administration.
9. The method of claim 7 wherein the pharmacological substance described in claims 3-5 is active when administered in doses of 0,1-30 µg/kg of the body weight.